Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Immunophenotyping of Acute Myeloid Leukemia.

Galera PK, Jiang C, Braylan R.

Methods Mol Biol. 2019;2032:281-296. doi: 10.1007/978-1-4939-9650-6_15.

PMID:
31522424
2.

Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates.

Dulau-Florea A, Maric I, Calvo KR, Braylan RC.

Semin Hematol. 2019 Jan;56(1):65-68. doi: 10.1053/j.seminhematol.2018.05.011. Epub 2018 May 27. Review.

PMID:
30573047
3.

The challenging task of enumerating blasts in the bone marrow.

Hodes A, Calvo KR, Dulau A, Maric I, Sun J, Braylan R.

Semin Hematol. 2019 Jan;56(1):58-64. doi: 10.1053/j.seminhematol.2018.07.001. Epub 2018 Aug 16.

PMID:
30573046
4.

Advances in diagnostic hematopathology.

Calvo KR, Braylan RC.

Semin Hematol. 2019 Jan;56(1):1. doi: 10.1053/j.seminhematol.2018.07.002. Epub 2018 Jul 19. No abstract available.

PMID:
30573038
5.

Bone Marrow as a Source of Cells for Paroxysmal Nocturnal Hemoglobinuria Detection.

Dulau-Florea AE, Young NS, Maric I, Calvo KR, Dunbar CE, Townsley DM, Winkler T, Monreal M, Jiang C, Jordan EK, Braylan RC.

Am J Clin Pathol. 2018 Jul 31;150(3):273-282. doi: 10.1093/ajcp/aqy053.

PMID:
29982419
6.

Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.

Salem DA, Korde N, Venzon DJ, Liewehr DJ, Maric I, Calvo KR, Braylan R, Tembhare PR, Yuan CM, Landgren CO, Stetler-Stevenson M.

Leuk Lymphoma. 2018 Jan;59(1):178-186. doi: 10.1080/10428194.2017.1321746. Epub 2017 May 25.

7.

Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD.

Dulau Florea AE, Braylan RC, Schafernak KT, Williams KW, Daub J, Goyal RK, Puck JM, Rao VK, Pittaluga S, Holland SM, Uzel G, Calvo KR.

J Allergy Clin Immunol. 2017 Mar;139(3):1032-1035.e6. doi: 10.1016/j.jaci.2016.08.028. Epub 2016 Sep 30. No abstract available.

8.

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.

Niemann CU, Herman SE, Maric I, Gomez-Rodriguez J, Biancotto A, Chang BY, Martyr S, Stetler-Stevenson M, Yuan CM, Calvo KR, Braylan RC, Valdez J, Lee YS, Wong DH, Jones J, Sun C, Marti GE, Farooqui MZ, Wiestner A.

Clin Cancer Res. 2016 Apr 1;22(7):1572-82. doi: 10.1158/1078-0432.CCR-15-1965. Epub 2015 Dec 9.

9.

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O.

JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.

10.

JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.

Calvo KR, Price S, Braylan RC, Oliveira JB, Lenardo M, Fleisher TA, Rao VK.

Blood. 2015 Apr 30;125(18):2753-8. doi: 10.1182/blood-2014-11-567917. Epub 2015 Feb 17. Review.

11.

Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individuals.

Montezuma-Rusca JM, Moir S, Kardava L, Buckner CM, Louie A, Kim LJ, Santich BH, Wang W, Fankuchen OR, Diaz G, Daub JR, Rosenzweig SD, Chun TW, Li Y, Braylan RC, Calvo KR, Fauci AS.

J Immunol. 2015 Mar 15;194(6):2561-8. doi: 10.4049/jimmunol.1402424. Epub 2015 Feb 13.

12.

GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia.

Ganapathi KA, Townsley DM, Hsu AP, Arthur DC, Zerbe CS, Cuellar-Rodriguez J, Hickstein DD, Rosenzweig SD, Braylan RC, Young NS, Holland SM, Calvo KR.

Blood. 2015 Jan 1;125(1):56-70. doi: 10.1182/blood-2014-06-580340. Epub 2014 Oct 30.

13.

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.

Manasanch EE, Salem DA, Yuan CM, Tageja N, Bhutani M, Kwok M, Kazandjian D, Carter G, Steinberg SM, Zuchlinski D, Mulquin M, Calvo K, Maric I, Roschewski M, Korde N, Braylan R, Landgren O, Stetler-Stevenson M.

Leuk Lymphoma. 2015 May;56(5):1416-24. doi: 10.3109/10428194.2014.955020. Epub 2014 Oct 30.

14.

LIN28A expression reduces sickling of cultured human erythrocytes.

de Vasconcellos JF, Fasano RM, Lee YT, Kaushal M, Byrnes C, Meier ER, Anderson M, Rabel A, Braylan R, Stroncek DF, Miller JL.

PLoS One. 2014 Sep 4;9(9):e106924. doi: 10.1371/journal.pone.0106924. eCollection 2014.

15.

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.

Haematologica. 2014 Jun;99(6):e81-3. doi: 10.3324/haematol.2013.103085. Epub 2014 Mar 21. No abstract available.

16.

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.

Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M.

Leuk Res. 2014 Mar;38(3):371-6. doi: 10.1016/j.leukres.2013.12.007. Epub 2013 Dec 11.

17.

Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma.

Manasanch EE, Braylan R, Stetler-Stevenson M, Yuan C, Gounden V, Korde N, Tageja N, Bhutani M, Calvo K, Maric I, Roschewski M, Staudt LM, Landgren O.

Leuk Lymphoma. 2014 Jun;55(6):1402-3. doi: 10.3109/10428194.2013.831091. Epub 2013 Dec 2. No abstract available.

18.

Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.

Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O.

Leuk Lymphoma. 2013 Oct;54(10):2215-8. doi: 10.3109/10428194.2013.764419. Epub 2013 Jul 29.

PMID:
23311294
19.

Flow cytometric analysis of immunoglobulin heavy chain expression in B-cell lymphoma and reactive lymphoid hyperplasia.

Grier DD, Al-Quran SZ, Cardona DM, Li Y, Braylan RC.

Int J Clin Exp Pathol. 2012;5(2):110-8. Epub 2012 Feb 12.

20.

Long-term disease control of refractory anaplastic large cell lymphoma with vinblastine.

Garner R, Li Y, Gray B, Zori R, Braylan R, Wall J, Hunger SP.

J Pediatr Hematol Oncol. 2009 Feb;31(2):145-7. doi: 10.1097/MPH.0b013e31819146f8.

PMID:
19194204
21.

The publishing game: reflections of an editorial team.

Crawford JM, Ketcham CM, Braylan R, Morel L, Terada N, Turner JR, Yachnis AT.

Lab Invest. 2008 Dec;88(12):1258-63. doi: 10.1038/labinvest.2008.113.

22.

Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth.

Sayyah J, Magis A, Ostrov DA, Allan RW, Braylan RC, Sayeski PP.

Mol Cancer Ther. 2008 Aug;7(8):2308-18. doi: 10.1158/1535-7163.MCT-08-0279.

23.

Low viral load post-transplant lymphoproliferative disease localized within the tongue.

Henry DD, Hunger SP, Braylan RC, Dharnidharka VR.

Transpl Infect Dis. 2008 Dec;10(6):426-30. doi: 10.1111/j.1399-3062.2008.00328.x. Epub 2008 Jul 22.

PMID:
18657087
24.

Intracranial myeloid sarcoma.

Grier DD, Al-Quran SZ, Gray B, Li Y, Braylan R.

Br J Haematol. 2008 Sep;142(5):681. doi: 10.1111/j.1365-2141.2008.07169.x. Epub 2008 May 8. No abstract available.

PMID:
18477037
25.

Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.

Liu H, Yuan C, Heinerich J, Braylan R, Chang M, Wingard J, Moreb J.

Leuk Lymphoma. 2008 Feb;49(2):306-14. doi: 10.1080/10428190701813018.

PMID:
18231918
26.

2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications.

Davis BH, Holden JT, Bene MC, Borowitz MJ, Braylan RC, Cornfield D, Gorczyca W, Lee R, Maiese R, Orfao A, Wells D, Wood BL, Stetler-Stevenson M.

Cytometry B Clin Cytom. 2007;72 Suppl 1:S5-13.

27.

Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.

Al-Quran SZ, Yang L, Magill JM, Braylan RC, Douglas-Nikitin VK.

Hum Pathol. 2007 Dec;38(12):1779-87. Epub 2007 Aug 21.

28.

2006 Bethesda International Consensus Conference on Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasia.

Stetler-Stevenson M, Davis B, Wood B, Braylan R.

Cytometry B Clin Cytom. 2007;72 Suppl 1:S3. No abstract available.

29.

Spatial distribution of blood vessels and CD34+ hematopoietic stem and progenitor cells within the marrow cavities of human cancellous bone.

Watchman CJ, Bourke VA, Lyon JR, Knowlton AE, Butler SL, Grier DD, Wingard JR, Braylan RC, Bolch WE.

J Nucl Med. 2007 Apr;48(4):645-54.

30.

Discordant expression of CD20 by flow cytometry and immunohistochemistry in a patient responding to rituximab: an unusual mechanism.

Walsh KJ, Al-Quran SZ, Li Y, Braylan RC, Lynch JW Jr.

Clin Lymphoma Myeloma. 2007 Jan;7(4):319-22.

PMID:
17324342
31.

Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation.

Yang F, Li Y, Braylan R, Hunger SP, Yang LJ.

Pediatr Blood Cancer. 2008 Feb;50(2):415-8.

33.

In hematopathology, love is everywhere.

Al-Quran SZ, Al-Abbadi M, Braylan RC.

Arch Pathol Lab Med. 2004 Nov;128(11):1309. No abstract available.

PMID:
15504075
34.

DRAQ5-based DNA content analysis of hematolymphoid cell subpopulations discriminated by surface antigens and light scatter properties.

Yuan CM, Douglas-Nikitin VK, Ahrens KP, Luchetta GR, Braylan RC, Yang L.

Cytometry B Clin Cytom. 2004 Mar;58(1):47-52.

35.
36.

Management of neurotropic low-grade B-cell lymphoma: report of two cases.

Garcia-Serra A, Price Mendenhall N, Hinerman RW, Lynch JW Jr, Braylan RC, Mancuso AA.

Head Neck. 2003 Nov;25(11):972-6.

PMID:
14603459
37.

Endothelial stimulation by small lymphocytic lymphoma correlates with secreted levels of basic fibroblastic growth factor.

Rimsza L, Pastos K, Massey K, Braylan R.

Br J Haematol. 2003 Mar;120(5):753-8.

PMID:
12614205
38.

All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia.

Li SW, Tang D, Ahrens KP, She JX, Braylan RC, Yang L.

Blood. 2003 Mar 1;101(5):1977-80. Epub 2002 Oct 17.

PMID:
12393392
39.

AML, angiogenesis, and prognostic variables.

Rimsza LM, Ahrens KP, Massey JK, Pastos KM, Mainwaring MG, Braylan RC.

Blood. 2002 Aug 15;100(4):1517-8. No abstract available.

PMID:
12184281
40.

Regarding the loss of CD20 after rituximab therapy.

Lee R, Braylan RC.

Br J Haematol. 2002 Sep;118(3):927. No abstract available.

PMID:
12181075
42.

Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma.

Lynch JW, Hei DL, Braylan RC, Rimzsa LM, Staab EV, Bewsher CJ, Mendenhall NP, Hudson JK.

Am J Clin Oncol. 2002 Aug;25(4):391-7.

PMID:
12151972
43.

Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.

Mainwaring MG, Rimsza LM, Chen SF, Gomez SP, Weeks FW, Reddy V, Lynch J, May WS, Kahn S, Moreb J, Leather H, Braylan R, Rowe TC, Fieniewicz KJ, Wingard JR.

Leuk Lymphoma. 2002 May;43(5):989-99.

PMID:
12148910
44.

Langerhans cell granulomatosis manifested as pigmented villonodular synovitis.

Pantazis CG, Templeton K, Tawfik OW, Braylan R.

J South Orthop Assoc. 2001 Winter;10(4):230-5.

PMID:
12132822
45.

Progress toward analysis of D8/17 binding to B cells in children with obsessive compulsive disorder and/or chronic tic disorder.

Murphy TK, Benson N, Zaytoun A, Yang M, Braylan R, Ayoub E, Goodman WK.

J Neuroimmunol. 2001 Nov 1;120(1-2):146-51.

PMID:
11694329
46.
47.
48.

Flow cytometric analysis of lymphomas and lymphoproliferative disorders.

Stetler-Stevenson M, Braylan RC.

Semin Hematol. 2001 Apr;38(2):111-23. Review.

PMID:
11309693
49.

Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting.

Braylan RC, Orfao A, Borowitz MJ, Davis BH.

Cytometry. 2001 Feb 15;46(1):23-7. Review. Erratum in: Cytometry 2001 Apr 15;46(2):119.

50.

Flow cytometric analysis of hematologic neoplasia.

Braylan RC, Anderson JB.

Methods Mol Med. 2001;55:217-30. doi: 10.1385/1-59259-074-8:217.

PMID:
21312110

Supplemental Content

Loading ...
Support Center